RE:RE:RE:RE:RE:RE:RE:Updates?Pandora wrote: enriquesuave wrote: "Enveloped viruses can cause persistent infections and must transfer from host to host. Examples of enveloped viruses include ones that cause notorious diseases in humans, such as COVID-19, Influenza, Hepatitis B and C, and Hemorrhagic Fever (Ebola Virus Disease)." As well as HIV, Mumps and measles plus more.
I still find it surprising that they have spent billions to come up with a number of vaccines but in 10 months they have done almost nothing in finding a good therapeutic to fix a person once they contract the disease. Why is that? Why have they totally dragged their feet on this component? It's been the biggest necessity since this whole thing started 10 months ago and the results are pathetic. Even something like CYDY's Leronlimab which has been around for a few years and has a good safety profile from a number of trials has now got to go full time for a 390 patient double blind Phase 2/3 trial and gets not fast track even though their Phase 2B showed good results. It just drags on and on while the death rate keeps growing. Everybody is all twitterpated over the vaccines but they're not helping the sick people.
Well said Pandora.
And what ever happened to Ivermectin as a potential treatment? Unfortunately, it seems to have gotten little attention or peer review by the global & national health authorities like the W.H.O., NIH & CDC. It would be nice for health care providers to get some kind of serious guidance or statement (good or bad) on its use or potential....as new cases & death counts rise. Fortunately, death "rates" have gone down relative to new cases, but it doesn't lessen the grief.
I agree, too little attention is being paid to therapeutics. However, if you can produce a 95% effective vaccine, you'll practically own the market for that illness. And more than likely, you will be generating "long term" revenue (though with comparatively narrow margins) as there's a good chance Covid-19 will become endemic & people will likely need boosters or yearly vaccinations. Multiple or yearly vaccinations is generally the rule of thumb for rapidly mutating RNA viruses like Covid-19, influenza, etc. Covid dropped a golden egg in Big Pharma's lap & they quickly capitalized with plenty of "new" cash in the till to go along with their intellectual & technical expertise. All JMO.
Also, when you already have two vaccines ready for market with such high efficacy, I would hope Theralase doesn't spend a single dime more of their (our) own money on vaccine development. As Enrique noted, that endeavor should be solely supported by grant/university monies imo. We've learned more than enough from a hundred yrs of experience with influenza & from the new-age & misled anti-vaxxers that despite major attempts at mass vaccination, there will still be a great need for effective therapeutics. If Theralase has to spend a dime more at U of M (hopefully not), I vote it be spent on saving lives & not just protecting them. We desperately need a better therapeutic.